Myo-inositol: A marker of reactive astrogliosis in glial tumors?

NMR in Biomedicine

Volumn 21, Issue 3, 2008, Pages 233-241

  Hattingen, Elke ^a   Raab, Peter ^a   Franz, Kea ^a   Zanella, Friedhelm E ^a   Lanfermann, Heinrich ^a   Pilatus, Ulrich ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

3 T; 1H MRS; Gliomas; Gliomatosis; Myo inositol; Short TE

Indexed keywords

BIOMEDICAL ENGINEERING; BRAIN; PATHOLOGY; SURGERY;

ASTROGLIOSIS; GLIAL TUMORS; GLIOMAS; GLIOMATOSIS; MYO-INOSITOL;

TUMORS;

CREATINE; CREATINE PHOSPHATE; INOSITOL; STEROID; TRIMETHYLAMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; ASTROCYTOSIS; BRAIN LEVEL; CANCER GRADING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; GLIOMA; GLIOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELAXATION TIME; TUMOR GROWTH;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE PROCESSING, COMPUTER-ASSISTED; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 41949102082     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1186     Document Type: Article

References (55)

1. 1H-magnetic resonance spectroscopy. J. Neurol. 2005; 252: 1229-1234.
2. Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, Kolson D, Schifitto G, Jarvik JG, Miller EN, Lenkinski R, Gonzalez G, Navia BA. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuro-Image. 2004; 23: 1336-1347.
3. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am. J. Neuroradiol. 2000; 21: 1645-1649.
4. Chang L, Ernst T, Osborn D, Seltzer W, Leonido-Yee M, Poland RE. Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. Arch. Neurol. 1998; 55: 305-311.
5. Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrie-Attarian M, Ranjeva JP, Fuentes S, Viout P, Figarella-Branger D, Cozzone PJ. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J. Neurosurg. 2003; 98: 269-276.
6. Gutowski NJ, Gomez-Anson B, Torpey N, Revesz T, Miller D, Rudge P. Oligodendroglial gliomatosis cerebri: (1)H-MRS suggests elevated glycine/ inositol levels. Neuroradiology 1999; 41: 650-653.
7. Saraf-Lavi E, Bowen BC, Pattany PM, Sklar EM, Murdoch JB, Petito CK. Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels. AJNR Am. J. Neuroradiol. 2003; 24: 946-951.
8. Mohana-Borges AV, Imbesi SG, Dietrich R, Alksne J, Amjadi DK. Role of proton magnetic resonance spectroscopy in the diagnosis of gliomatosis cerebri: a unique pattern of normal choline but elevated Myo-inositol metabolite levels. J. Comput. Assist. Tomogr. 2004; 28: 103-105.
9. 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR Am. J. Neuroradiol. 2006; 27: 560-572.
10. Pyhtinen J. Proton MR spectroscopy in gliomatosis cerebri. Neuroradiology 2000; 42: 612-615.
11. 1H magnetic resonance spectroscopy of childhood brain tumours. Childs Nerv. Syst. 2007; 23: 163-169.
12. Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, Frahm J. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr Neurol. 2000; 23: 22-31.
13. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am. J. Neuroradiol. 2006; 27: 475-487.
14. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30: 672-679.
15. Seeger U, Klose U, Mader I, Grodd W, Nagele T. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn. Reson. Med. 2003; 49: 19-28.
16. Michaelis T, Merboldt K, Bruhn H, Hänicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993; 187: 219-227.
17. 1H metabolite relaxation times at 3.0 tesla: measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J. Magn. Reson. Imaging 2004; 19: 537-545.
18. Wiedermann D, Schuff N, Matson GB, Sober BJ, Du AT, Maudsley AA, Weiner MW. Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: metabolite distributions and reliability. Magn. Reson. Imaging 2001; 19: 1073-1080.
19. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours, Kleihues P, Cavenee WK (eds). International Agency for Research on Cancer (IARC Press): Lyon, France, 2000.
20. 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed. 2004; 17: 361-381.
21. Majos C, Julia-Sape M, Alonso J, Serrallonga M, Aguilera C, Acebes JJ, Arus C, Gili J. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am. J Neuroradiol. 2004; 25: 1696-1704.
22. Schober R, Mai JK, Volk B, Wechsler W. Gliomatosis cerebri: bioptical approach and neuropathological verification. Acta Neurochir (Wien.) 1991; 113: 131-137.
23. Artigas J, Cervos-Navarro J, Iglesias JR, Ebhardt G. Gliomatosis cerebri: clinical and histological findings. Clin. Neuropathol. 1985; 4: 135-148.
24. Thurston JH, Sherman WR, Hauhart RE, Kloepper RF. myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr. Res. 1989; 26: 482-485.
25. Lee JH, Arcinue E, Ross BD. Brief report: organic osmolytes in the brain of an infant with hypernatremia. N. Engl. J. Med. 1994; 331: 439-442.
26. Lohr JW, McReynolds J, Grimaldi T, Acara M. Effect of acute and chronic hypernatremia on myoinositol and sorbitol concentration in rat brain and kidney. Life Sci. 1988; 43: 271-276.
27. Wiese TJ, Dunlap JA, Conner CE, Grzybowski JA, Lowe WL Jr, Yorek MA. Osmotic regulation of Na-myo-inositol cotransporter mRNA level and activity in endothelial and neural cells. Am. J. Physiol 1996; 270: C990-C997.
28. Paredes A, McManus M, Kwon HM, Strange K. Osmoregulation of Na(+)-inositol cotransporter activity and mRNA levels in brain glial cells. Am. J. Physiol 1992; 263: C1282-C1288.
29. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997; 387: 673-676.
30. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989; 341: 197-205.
31. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 1993; 15: 289-298.
32. 1H MRS study. Neurology 2000; 55: 210-217.
33. Bruhn H, Frahm J, Merboldt KD, Hanicke W, Hanefeld F, Christen HJ, Kruse B, Bauer HJ. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann. Neurol. 1992; 32: 140-150.
34. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
35. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, Bruck W. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am. J. Neuroradiol. 1999; 20: 1619-1627.
36. Brockmann K, Dechent P, Wilken B, Rusch O, Frahm J, Hanefeld F. Proton MRS profile of cerebral metabolic abnormalities in Krabbe disease. Neurology 2003; 60: 819-825.
37. Alkan A, Kutlu R, Sigirci A, Aslan M, Sarac K, Yakinci C. Subacute sclerosing panencephalitis with fulminating course: follow-up magnetic resonance spectroscopy (MRS) findings. J. Child Neurol. 2004; 19: 233-238.
38. Kruse B, Hanefeld F, Christen HJ, Bruhn H, Michaelis T, Hanicke W, Frahm J. Alterations of brain metabolites in meta-chromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J. Neurol. 1993; 241: 68-74.
39. Mizuno S, Takahashi Y, Kato Z, Goto H, Kondo N, Hoshi H. Magnetic resonance spectroscopy of tubers in patients with tuberous sclerosis. Acta Neurol. Scand. 2000; 102: 175-178.
40. Herminghaus S, Pilatus U, Moller-Hartmann W, Raab P, Lanfermann H, Schlote W, Zanella FE. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed. 2002; 15: 385-392.
41. Hanefeld FA, Brockmann K, Pouwels PJ, Wilken B, Frahm J, Dechent P. Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination. Neurology 2005; 65: 701-706.
42. Li X, Lu Y, Pirzkall A, McKnight T, Nelson SJ. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J. Magn. Reson. Imaging 2002; 16: 229-237.
43. Moller A, Hamprecht B. Creatine transport in cultured cells of rat and mouse brain. J. Neurochem. 1989; 52: 544-550.
44. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 1993; 13: 981-989.
45. Dringen R, Verleysdonk S, Hamprecht B, Willker W, Leibfritz D, Brand A. Metabolism of glycine in primary astroglial cells: synthesis of creatine, serine, and glutathione. J. Neurochem. 1998; 70: 835-840.
46. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 1994; 35: 606-613.
47. 1H spectroscopic imaging. Ann. Neurol. 1994; 36: 157-165.
48. van der Knaap MS, Naidu S, Pouwels PJ, Bonavita S, van Coster R, Lagae L, Sperner J, Surtees R, Schiffmann R, Valk J. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am. J. Neuroradiol. 2002; 23: 1466-1474.
49. Chang L, Ernst T, Tornatore C, Aronow H, Melchor R, Walot I, Singer E, Cornford M. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997; 48: 836-845.
50. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of astrocytic tumors: an in vitro study. Neurol. Med. Chir (Tokyo) 1993; 33: 350-359.
51. 1H NMR spectroscopic investigation. NMR Biomed. 2005; 18: 371-382.
52. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997; 10: 2-12.
53. Prescot AP, de BF, Wang L, Brown J, Jensen JE, Kaufman MJ, Renshaw PF. In vivo detection of brain glycine with echo-time-averaged (1)H magnetic resonance spectroscopy at 4.0 T. Magn Reson. Med. 2006; 55: 681-686.
54. Bartha R, Drost DJ, Menon RS, Williamson PC. Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn. Reson. Med. 2000; 44: 185-192.
55. 1H proton spectroscopic imaging of the human brain. Magn. Reson. Imaging 2004; 22: 523-528.